Dicerna Pharmaceuticals reported $20.67M in Selling and Administration Expenses for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Acceleron Pharma XLRN:US $ 31.06M 4.85M
Agenus AGEN:US $ 16.35M 3.68M
Alnylam Pharmaceuticals ALNY:US $ 154.9M 11.39M
Amgen AMGN:US $ 1.25B 519M
Arrowhead Research ARWR:US $ 16.19M 7.54M
Biogen BIIB:US $ 637.3M 42.3M
Bluebird Bio BLUE:US $ 86.87M 9.9M
Dicerna Pharmaceuticals DRNA:US $ 20.67M 2.09M
Exelixis EXEL:US $ 102.35M 19.91M
Gilead Sciences GILD:US $ 1.34B 297M
GlaxoSmithKline GSK:LN 2.5B 183M
Immunogen IMGN:US $ 9.73M 481K
Intercept Pharmaceuticals ICPT:US $ 57.65M 1.62M
Intrexon XON:US $ 18.7M 8.94M
Karyopharm Therapeutics KPTI:US $ 37.65M 3.72M
Macrogenics MGNX:US $ 15.23M 198K
Merk MRK:US $ 2.25B 376M
Mirati Therapeutics MRTX:US $ 28.35M 3.01M
Pfizer PFE:US $ 2.79B 134M
Regeneron Pharmaceuticals REGN:US $ 405.6M 102.1M
Regulus Therapeutics RGLS:US $ 2.48M 400K
Ultragenyx Pharmaceutical RARE:US $ 53.26M 2.22M